Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Protagonist Therapeutics, Inc.
  6. News
  7. Summary
    PTGX   US74366E1029

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
9.080 USD   -2.37%
06/02PROTAGONIST THERAPEUTICS, INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/01Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
PR
05/26Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bowel Disease Treatment

04/26/2022 | 02:55pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about PROTAGONIST THERAPEUTICS, INC.
06/02PROTAGONIST THERAPEUTICS, INC : Submission of Matters to a Vote of Security Holders (form ..
AQ
06/01Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference
PR
05/26Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results i..
CI
05/18Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reitera..
MT
05/05PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
05/05SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outpe..
MT
05/04PROTAGONIST THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
04/26Protagonist Therapeutics' Shares Plummet After Reporting Trial Data for Inflammatory Bo..
MT
04/26Top Midday Decliners
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 31,9 M - -
Net income 2022 -157 M - -
Net cash 2022 174 M - -
P/E ratio 2022 -2,87x
Yield 2022 -
Capitalization 442 M 442 M -
EV / Sales 2022 8,39x
EV / Sales 2023 33,3x
Nbr of Employees 122
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 9,08 $
Average target price 40,00 $
Spread / Average Target 341%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-73.45%442
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371